TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MannKind ( (MNKD) ) just unveiled an announcement.
On October 7, 2025, MannKind completed the acquisition of scPharma, making it a wholly-owned subsidiary. This acquisition was facilitated through a merger agreement and involved a contingent value rights agreement, which outlines milestone payments based on FDA approval and sales targets. The acquisition was funded by MannKind’s available cash and borrowings under a credit agreement, with a total transaction cost of approximately $296.5 million. The merger aims to enhance MannKind’s market position by integrating scPharma’s drug-device combination products and leveraging potential sales growth.
The most recent analyst rating on (MNKD) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page.
Spark’s Take on MNKD Stock
According to Spark, TipRanks’ AI Analyst, MNKD is a Neutral.
MannKind’s overall stock score reflects a mix of strong technical momentum and positive corporate developments, offset by financial risks and high valuation concerns. The company’s strategic initiatives and recent acquisitions are promising, but financial stability remains a key area for improvement.
To see Spark’s full report on MNKD stock, click here.
More about MannKind
Average Trading Volume: 4,089,615
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
Find detailed analytics on MNKD stock on TipRanks’ Stock Analysis page.